title: Morphine and hydromorphone-induced hyperalgesia in a hospice patient.
abstract: Opioids including morphine and hydromorphone are widely used for control of moderate to severe pain and dyspnea in hospice and palliative care patients. Accumulation of the active morphine-3-glucuronide (M3G) and hydromorphone-3-glucuronide (H3G) metabolites is one proposed mechanism for the development of neuroexcitatory effects including allodynia and opioid-induced hyperalgesia (OIH). We report the case of a 43-year-old female hospice patient with metastatic non-small cell lung cancer who initially developed allodynia following morphine administration and again following administration of hydromorphone. The allodynia resolved both times following the discontinuation of the opioid and rotation to a different opioid regimen. Potential opioid-induced neuroexcitatory treatment options include opioid rotation to an agent with inactive metabolites, use of adjuvant pain medications for opioid-sparing effects, management of undesired symptoms (e.g., myoclonus), or increasing opioid clearance with intravenous (IV) fluids. Although the incidence is not well defined in the literature, hospice and palliative care clinicians should suspect OIH in patients with allodynia and/or hyperalgesia, especially when repeated dose escalations do not improve analgesia or pain escalates following opioid dose titration.
authors.affiliation: Department of Pharmacy Practice, Wegmans School of Pharmacy, St. John Fisher College, Rochester, New York 14618, USA. kjuba@sjfc.edu
authors.forename: Katherine M
authors.initials: KM
authors.lastname: Juba
authors.forename: Robert G
authors.initials: RG
authors.lastname: Wahler
authors.forename: Susan M
authors.initials: SM
authors.lastname: Daron
mesh_terms: D000328:Adult; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000150:complications / Q000188:drug therapy; D003692:Delayed-Action Preparations; D005260:Female; D005283:Fentanyl / Q000008:administration & dosage / Q000627:therapeutic use*; D017051:Hospice Care / Q000379:methods / Q000592:standards*; D006801:Humans; D004091:Hydromorphone / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006930:Hyperalgesia / Q000139:chemically induced*; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000150:complications / Q000188:drug therapy; D009020:Morphine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D009362:Neoplasm Metastasis; D059408:Pain Management / Q000379:methods*; D010166:Palliative Care / Q000379:methods / Q000592:standards*
chemical_list: D000701:Analgesics, Opioid; D003692:Delayed-Action Preparations; D009020:Morphine; D004091:Hydromorphone; D005283:Fentanyl